Are psychotic-like experiences related to a discontinuation of cannabis consumption in young adults?

Laura S Daedelow¹, Tobias Banaschewski², Moritz Berning³, Arun L W Bokde⁴, Rüdiger Brühl⁵, Erin Burke Quinlan⁶, H Valerie Curran⁷, Sylvane Desrivières⁶, Herta Flor⁸, Antoine Grigis⁹, Hugh Garavan¹⁰, Anita Hardon³, Jakob Kaminski¹¹, Jean-Luc Martinot¹², Marie-Laure Paillère Martinot¹³, Eric Artiges¹⁴, Hayley Murray³, Frauke Nees¹⁵, Nicole Y L Oei¹⁶, Dimitri Papadopoulos Orfanos⁹, Tomáš Paus¹⁷, Luise Poustka¹⁸, Sarah Hohmann², Sabina Millenet², Annika Rosenthal¹¹, Juliane H Fröhner¹⁹, Michael N Smolka¹⁹, Henrik Walter¹¹, Robert Whelan²⁰, Reinout W Wiers²¹, Gunter Schumann²², Andreas Heinz¹¹; ERANID Consortium; IMAGEN Consortium

Affiliations

¹ Department of Psychiatry and Psychotherapy CCM, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. Electronic address: laura.daedelow@charite.de.
² Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany.
³ Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterdam, the Netherlands.
⁴ Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
⁵ Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Germany.
⁶ Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, United Kingdom.
⁷ Clinical Psychopharmacology Unit, University College London, London, United Kingdom.
⁸ Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, Mannheim, Germany; Department of Psychology, School of Social Sciences, University of Mannheim, 68131 Mannheim, Germany.
⁹ NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France.
¹⁰ Departments of Psychiatry and Psychology, University of Vermont, 05405 Burlington, VT, USA.
¹¹ Department of Psychiatry and Psychotherapy CCM, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
¹² Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-sur-Yvette, France.
¹³ Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli; and AP-HP.Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France.
¹⁴ Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli; and Psychiatry Department 91G16, Orsay Hospital, France.
¹⁵ Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany; Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, Mannheim, Germany; Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, Kiel, Germany.
¹⁶ Research Priority Area (RPA) Yield, University of Amsterdam, Amsterdam, the Netherlands; Developmental Psychology (Addiction Development and Psychopathology ADAPT-lab), University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Brain and Cognition (ABC), University of Amsterdam, Amsterdam, the Netherlands.
¹⁷ Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Departments of Psychology and Psychiatry, University of Toronto, Toronto, Ontario M6A 2E1, Canada.
¹⁸ Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, von-Siebold-Str. 5, 37075 Göttingen, Germany.
¹⁹ Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.
²⁰ School of Psychology, Global Brain Health Institute, Trinity College Dublin, Ireland.
²¹ Department of Developmental Psychology, Adapt Lab, Research Priority Area Yield, University of Amsterdam, Nieuwe Achtergracht 129-B, 1018 WS Amsterdam, the Netherlands.
²² Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, United Kingdom; PONS Research Group, Dept of Psychiatry and Psychotherapy, Campus Charite Mitte, Humboldt University, Berlin and Leibniz Institute for Neurobiology, Magdeburg, Germany, and Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan University, Shanghai, PR China.

PMID: 33493775
DOI: 10.1016/j.schres.2021.01.002

Are psychotic-like experiences related to a discontinuation of cannabis consumption in young adults?

Laura S Daedelow et al. Schizophr Res. 2021 Feb.

. 2021 Feb:228:271-279.

doi: 10.1016/j.schres.2021.01.002. Epub 2021 Jan 23.

Authors

Affiliations

¹ Department of Psychiatry and Psychotherapy CCM, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. Electronic address: laura.daedelow@charite.de.
² Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany.
³ Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterdam, the Netherlands.
⁴ Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
⁵ Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Germany.
⁶ Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, United Kingdom.
⁷ Clinical Psychopharmacology Unit, University College London, London, United Kingdom.
⁸ Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, Mannheim, Germany; Department of Psychology, School of Social Sciences, University of Mannheim, 68131 Mannheim, Germany.
⁹ NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France.
¹⁰ Departments of Psychiatry and Psychology, University of Vermont, 05405 Burlington, VT, USA.
¹¹ Department of Psychiatry and Psychotherapy CCM, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
¹² Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-sur-Yvette, France.
¹³ Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli; and AP-HP.Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France.
¹⁴ Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli; and Psychiatry Department 91G16, Orsay Hospital, France.
¹⁵ Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany; Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, Mannheim, Germany; Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, Kiel, Germany.
¹⁶ Research Priority Area (RPA) Yield, University of Amsterdam, Amsterdam, the Netherlands; Developmental Psychology (Addiction Development and Psychopathology ADAPT-lab), University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Brain and Cognition (ABC), University of Amsterdam, Amsterdam, the Netherlands.
¹⁷ Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Departments of Psychology and Psychiatry, University of Toronto, Toronto, Ontario M6A 2E1, Canada.
¹⁸ Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, von-Siebold-Str. 5, 37075 Göttingen, Germany.
¹⁹ Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.
²⁰ School of Psychology, Global Brain Health Institute, Trinity College Dublin, Ireland.
²¹ Department of Developmental Psychology, Adapt Lab, Research Priority Area Yield, University of Amsterdam, Nieuwe Achtergracht 129-B, 1018 WS Amsterdam, the Netherlands.
²² Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, United Kingdom; PONS Research Group, Dept of Psychiatry and Psychotherapy, Campus Charite Mitte, Humboldt University, Berlin and Leibniz Institute for Neurobiology, Magdeburg, Germany, and Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan University, Shanghai, PR China.

PMID: 33493775
DOI: 10.1016/j.schres.2021.01.002

Abstract

Objective: To assess changes in cannabis use in young adults as a function of psychotic-like experiences.

Method: Participants were initially recruited at age 14 in high schools for the longitudinal IMAGEN study. All measures presented here were assessed at follow-ups at age 19 and at age 22, respectively. Perceived stress was only assessed once at age 22. Ever users of cannabis (N = 552) gave qualitative and quantitative information on cannabis use and psychotic-like experiences using the Community Assessment of Psychic Experiences (CAPE). Of those, nearly all n = 549 reported to have experienced at least one psychotic experience of any form at age 19.

Results: Mean cannabis use increased from age 19 to 22 and age of first use of cannabis was positively associated with a change in cannabis use between the two time points. Change in cannabis use was not significantly associated with psychotic-like experiences at age 19 or 22. In exploratory analysis, we observed a positive association between perceived stress and the experience of psychotic experiences at age 22.

Conclusion: Age of first use of cannabis influenced trajectories of young cannabis users with later onset leading to higher increase, whereas the frequency of psychotic-like experiences was not associated with a change in cannabis use. The observed association between perceived stress and psychotic-like experiences at age 22 emphasizes the importance of stress experiences in developing psychosis independent of cannabis use.

Keywords: Age of first use; Cannabis discontinuation hypothesis; Cannabis use; Perceived stress; Psychotic-like experiences.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Banaschewski served in an advisory or consultancy role for Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or speaker's fee by Lilly, Medice, Novartis and Shire. He has been involved in clinical trials conducted by Shire & Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships. The other authors report no biomedical financial interests or potential conflicts of interest.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Are psychotic-like experiences related to a discontinuation of cannabis consumption in young adults?

Affiliations

Are psychotic-like experiences related to a discontinuation of cannabis consumption in young adults?

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical